This CME activity, derived from content presented at Maui Derm for Dermatologists 2021, will highlight recent advances in the treatment and management of moderate-to-severe atopic dermatitis, particularly in the adult patient population. The expert faculty, Drs. Jonathan Silverberg and Eric Simpson, will first review the immunopathology of atopic dermatitis, as well as current guidelines for both adolescents and adults. Recent clinical trial data, including that of JAK-1 Inhibitors, will be analyzed and clinical implications debated in an interactive panel format. The expert faculty will conclude with a review of the vital role that the interprofessional team plays in educating and caring for patients with atopic dermatitis. Upon completion of this educational activity, learners will gain insight into how to better care for and manage their patients with atopic dermatitis.
Dermatologists and dermatology advanced practice providers who are involved in the care and treatment of patients with moderate-to-severe atopic dermatitis
- Discuss the immunopathology, therapeutic targets including JAK-1 inhibitors, and recently updated guidelines for moderate-to-severe atopic dermatitis
- Analyze recent clinical trial data of current and emerging therapeutic options to treat adolescents and adults with moderate-to-severe atopic dermatitis
- Optimize the role of the dermatologic healthcare team in the management of adolescent and adult patients with moderate-to-severe atopic dermatitis
I. Immunopathology, JAK-1 Inhibitor-Based Therapeutic Targets, and Updated Guidelines for Adolescents and Adults with Moderate-to-Severe AD
II. Clinical Trial Update for Therapeutic Options, Including JAK-1 Inhibitors, for Moderate-to-Severe AD
III. Optimizing the Role of the Dermatology Care Professional to Treat Adolescents and Adults with AD
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Jonathan Silverberg, MD, PhD, MPH
|Consultant/Advisor: AbbVie Inc.; AFYX; Arena Pharmaceuticals Inc.; Asana BioSciences, LLC; BiomX; Bluefin Pharmaceuticals; Boehringer-Ingelheim; Celgene Corporation A Bristol Myers Squibb Company; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; Galderma; GlaxoSmithKline plc; Incyte; Kiniksa Pharmaceuticals, Ltd.; LEO Pharma, Inc.; LunaPharma; Menlo Therapeutics; Novartis AG; Pfizer, Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc.; Sanofi
Grant/Research Support: Galderma
Speakers Bureau: Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
|Eric Simpson, MD, MCR
|Consultant/Advisor: AbbVie Inc.; Dermira, Inc.; Eli Lilly and Company; Forte Biosciences, Inc.; Genzyme Corporation; Incyte; Janssen Global Services, LLC; Kyowa Kirin, Co., Ltd.; LEO Pharma, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.
Grant/Research Support: Eli Lilly and Company; Genzyme Corporation; Incyte; Kyowa Kirin, Co., Ltd.; LEO Pharma, Inc.; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
This activity has been supported by an independent educational grant from Pfizer Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].